As a member of the AstraZeneca Group, Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing novel autologous and allogeneic cell therapies for cancer and autoimmune diseases. Since its inception, Gracell has established a solid inhouse R&D system. Leveraging its proprietary FasTCAR and TruUCAR technology platforms and SMART CART™ technology modules, Gracell is researching new ways to address current challenges with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal T cell quality and barriers that limit their activity in solid tumors and autoimmune diseases.
Looking for a particular Gracell Biotechnologies employee's phone or email?
Gracell Biotechnologies Questions
The Gracell Biotechnologies annual revenue was $106 million in 2026.
Erin Li is the Vice President of Gracell Biotechnologies.
23 people are employed at Gracell Biotechnologies.
Gracell Biotechnologies is based in Shanghai, Shanghai.
The NAICS codes for Gracell Biotechnologies are [5417, 541, 54, 54171, 541713].
The SIC codes for Gracell Biotechnologies are [87, 873].
Top Gracell Biotechnologies Employees
-
Erin Li
Vice President at Gracell Biotechnologies
Shanghai, China2 -
Jing Jiao
Director at Gracell Biotechnologies
Somerville, MA, US21 -
Corrine Chen
HR Director at Gracell Biotechnologies
Shanghai, China4 -
2
-
4
Related Companies
